132 related articles for article (PubMed ID: 36976753)
1. Reallocating Cervical Cancer Preventive Service Spending from Low- to High-Value Clinical Scenarios.
Rockwell MS; Armbruster SD; Capucao JC; Russell KB; Rockwell JA; Perkins KE; Huffstetler AN; Mafi JN; Fendrick AM
Cancer Prev Res (Phila); 2023 Jul; 16(7):385-391. PubMed ID: 36976753
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Breast, Cervical, and Colorectal Cancer Screening: Patterns Among Women With Medicaid and Commercial Insurance.
Bonafede MM; Miller JD; Pohlman SK; Troeger KA; Sprague BL; Herschorn SD; Winer IH
Am J Prev Med; 2019 Sep; 57(3):394-402. PubMed ID: 31377088
[TBL] [Abstract][Full Text] [Related]
4. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
5. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
6. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
7. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
8. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
9. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020.
Chua KP; Conti RM; Becker NV
JAMA Netw Open; 2021 Oct; 4(10):e2129894. PubMed ID: 34661662
[TBL] [Abstract][Full Text] [Related]
11. Perceived Financial Barriers to Cervical Cancer Screening and Associated Cost Burden Among Low-Income, Under-Screened Women.
Biddell CB; Spees LP; Smith JS; Brewer NT; Des Marais AC; Sanusi BO; Hudgens MG; Barclay L; Jackson S; Kent EE; Wheeler SB
J Womens Health (Larchmt); 2021 Sep; 30(9):1243-1252. PubMed ID: 33851854
[No Abstract] [Full Text] [Related]
12. Avoiding Low-Value Care and Patient Financial Harm in Cervical Cancer Screening.
Sawaya GF; Dorismond VG
Cancer Prev Res (Phila); 2023 Jul; 16(7):363-364. PubMed ID: 37403658
[TBL] [Abstract][Full Text] [Related]
13. Frequency and Costs of Out-of-Network Bills for Outpatient Laboratory Services Among Privately Insured Patients.
Sen AP; Meiselbach MK; Wang Y; Eisenberg MD; Anderson GF
JAMA Intern Med; 2021 Jun; 181(6):834-841. PubMed ID: 33900358
[TBL] [Abstract][Full Text] [Related]
14. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
15. Effect of Out-of-Pocket Costs on Subsequent Mammography Screening.
Tran L; Chetlen AL; Leslie DL; Segel JE
J Am Coll Radiol; 2022 Jan; 19(1 Pt A):24-34. PubMed ID: 34748732
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
[TBL] [Abstract][Full Text] [Related]
18. Cost of care for the initial management of cervical cancer in women with commercial insurance.
Blanco M; Chen L; Melamed A; Tergas AI; Khoury-Collado F; Hou JY; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2021 Mar; 224(3):286.e1-286.e11. PubMed ID: 32818476
[TBL] [Abstract][Full Text] [Related]
19. Out-of-Pocket Costs for Colposcopy Among Commercially Insured Women From 2006 to 2019.
Fendrick AM; Dalton VK; Tilea A; Malone AM; Moniz MH
Obstet Gynecol; 2022 Jan; 139(1):113-115. PubMed ID: 34587620
[TBL] [Abstract][Full Text] [Related]
20. The effect of the Affordable Care Act on patient out-of-pocket cost and use of preventive cancer screenings in Massachusetts.
Steenland M; Sinaiko A; Glynn A; Fitzgerald T; Cohen J
Prev Med Rep; 2019 Sep; 15():100924. PubMed ID: 31333996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
